IMFINZI® and IMJUDO® Combo Improves Liver Cancer Outcomes

The drug combination demonstrated progression-free survival benefits in early-stage liver cancer patients.

Apr. 2, 2026 at 12:28pm

Got story updates? Submit your updates here. ›

AstraZeneca announced that its IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) combination therapy significantly improved progression-free survival in patients with early-stage liver cancer compared to standard of care treatment alone. The findings come from a late-stage clinical trial conducted by the pharmaceutical company.

Why it matters

This is an important development for liver cancer patients, as the disease is often diagnosed at later stages when treatment options are more limited. The IMFINZI and IMJUDO combination represents a potential new first-line therapy that could improve outcomes for those with early-stage liver cancer.

The details

The Phase III clinical trial evaluated the IMFINZI and IMJUDO regimen versus standard of care treatment in patients with unresectable hepatocellular carcinoma, the most common type of liver cancer. The combination therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to the control arm.

  • The clinical trial results were announced on April 2, 2026.

The players

AstraZeneca

A global biopharmaceutical company that developed the IMFINZI and IMJUDO combination therapy.

IMFINZI® (durvalumab)

An immunotherapy drug used to treat certain types of cancer.

IMJUDO® (tremelimumab-actl)

An investigational immunotherapy drug that is being studied in combination with IMFINZI.

Got photos? Submit your photos here. ›

What they’re saying

“These positive results demonstrate the potential of the IMFINZI and IMJUDO combination to improve outcomes for patients with early-stage liver cancer, an area of significant unmet need.”

— Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca

What’s next

AstraZeneca plans to submit the data to regulatory authorities for potential approval of the IMFINZI and IMJUDO combination as a new first-line treatment option for early-stage liver cancer.

The takeaway

The promising results from AstraZeneca's clinical trial suggest the IMFINZI and IMJUDO combination could become a new standard of care for patients diagnosed with early-stage liver cancer, potentially improving their chances of better outcomes.